menu
    • menu
    [{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Innoviva"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Innoviva"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"PAION UK LTD","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ PAION UK LTD","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ PAION UK LTD"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Tetraphase Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"La Jolla Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"La Jolla Pharmaceutical \/ La Jolla Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by La Jolla Pharmaceutical

    Menu

    La Jolla Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Recipient : Kingman Regional Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            November 08, 2023

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Recipient : Kingman Regional Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Recipient : University of New Mexico

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 24, 2023

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Recipient : University of New Mexico

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Innoviva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Innoviva to Acquire La Jolla Pharmaceutical Company

                            Details : Acquisition will strengthen Innoviva’s infectious disease portfolio with addition of GIAPREZA® (angiotensin II) and XERAVA® (eravacycline), and advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel a...

                            Product Name : Giapreza

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            November 07, 2022

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Innoviva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) ...

                            Details : XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.

                            Product Name : Xerava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2022

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Innoviva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Innoviva Completes Acquisition of La Jolla Pharmaceutical

                            Details : La Jolla brings to Innoviva an established product portfolio, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-...

                            Product Name : Giapreza

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            August 22, 2022

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Innoviva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : PAION UK LTD

                            Deal Size : $132.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and X...

                            Details : La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.

                            Product Name : Giapreza

                            Product Type : Peptide

                            Upfront Cash : $22.5 million

                            December 01, 2021

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : PAION UK LTD

                            Deal Size : $132.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Recipient : Northwestern University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Angiotensin II for Distributive Shock

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 27, 2021

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Recipient : Northwestern University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II/ Phase III

                            Recipient : University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Angiotensin II in Liver Transplantation

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 25, 2021

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II/ Phase III

                            Recipient : University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Recipient : University of Illinois, Chicago

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 27, 2020

                            Lead Product(s) : Angiotensin II

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Recipient : University of Illinois, Chicago

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Tetraphase Pharmaceuticals

                            Deal Size : $59.0‬ million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

                            Details : Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases.

                            Product Name : Xerava

                            Product Type : Other Small Molecule

                            Upfront Cash : $43.0 million

                            June 24, 2020

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Tetraphase Pharmaceuticals

                            Deal Size : $59.0‬ million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth